In last trading session, Summit Therapeutics Inc (NASDAQ:SMMT) saw 0.7 million shares changing hands with its beta currently measuring -1.02. Company’s recent per share price level of $1.93 trading at $0.07 or 3.76% at ring of the bell on the day assigns it a market valuation of $1.35B. That closing price of SMMT’s stock is at a discount of -199.48% from its 52-week high price of $5.78 and is indicating a premium of 65.8% from its 52-week low price of $0.66. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.22 million shares which gives us an average trading volume of 973.79K if we extend that period to 3-months.
For Summit Therapeutics Inc (SMMT), analysts’ consensus is at an average recommendation of a Hold while assigning it a mean rating of 3.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 0 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of $0 in the current quarter.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
Summit Therapeutics Inc (NASDAQ:SMMT) trade information
Upright in the green during last session for gaining 3.76%, in the last five days SMMT remained trading in the green while hitting it’s week-highest on Wednesday, 11/15/23 when the stock touched $1.93 price level, adding 5.85% to its value on the day. Summit Therapeutics Inc’s shares saw a change of -54.59% in year-to-date performance and have moved 1.31% in past 5-day. Summit Therapeutics Inc (NASDAQ:SMMT) showed a performance of 4.89% in past 30-days. Number of shares sold short was 9.48 million shares which calculate 9.92 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $4.00 to the stock, which implies a rise of 51.75% to its current value. Analysts have been projecting $4.00 as a low price target for the stock while placing it at a high target of $4.00. It follows that stock’s current price would drop -107.25% in reaching the projected high whereas dropping to the targeted low would mean a loss of -107.25% for stock’s current value.
Summit Therapeutics Inc (SMMT) estimates and forecasts
This year revenue growth is estimated to fall -92.30% from the last financial year’s standing.
Company posted $4.55 million and $192k of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -0.32% during past 5 years.
SMMT Dividends
Summit Therapeutics Inc is more likely to be releasing its next quarterly report on November 07 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
